BigHat Biosciences

Research on the record

• 2026-10-27BigHat and Anthropic improve two antibody leads over seven rounds, after finding one thermal measure did not measure what its name saidLevel 4 · Tested in the physical world

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-10-27Anthropic buys a one-person drug company and starts running drug programmes of its ownOrganizations
• 2026-09-24BigHat Biosciences raises $75M to take its AI-designed antibodies to clinical readoutsCapital
• 2026-09-01BigHat doses the first patient with BHB810, its first AI-designed drug in humansOrganizations

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-09-24Series C · $75MconfirmedLed by DFJ Growth, Premji Invest · With Catalio Capital Management, LG Technology Ventures, Amgen Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund, Andreessen Horowitz, Sigmas Group, 8VC, Alexandria Venture Investments, Discovery Ventures, GRIDS Capital, Intermountain Ventures, Quadrille Capital, Section 32Stated use: advance BHB810 and BHB299 to clinical readouts; scale data generation
• 2022-07-20Series B · $75MconfirmedLed by Section 32 · With Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Andreessen Horowitz, 8VC, AME Cloud Ventures, Gaingels, GRIDS CapitalStated use: scale Milliner and advance programs toward the clinic
• 2021-02-10Series A · $19MconfirmedLed by Andreessen Horowitz · With 8VC, AME Cloud Ventures, Innovation EndeavorsStated use: grow the team and platform, advance internal programs

Each round links to its line on the funding record, with its source.

Also in Protein design on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
• 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
• 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
• 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
• 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.
• 2026-02-26Generate:BiomedicinesIPO · $400MA Flagship company using generative AI to design protein drugs such as antibodies, peptides and enzymes, and developing them itself.

All 15 in this field →